The impact on your business

Ransomware is the digital version of kidnapping. Attackers break into your systems, lock up your data, and demand payment for its release. But unlike old-school kidnappers, they don’t just keep the hostage — they copy it too. For R&D-heavy companies, that hostage is your research pipeline: your trade secrets, trial data, and commercialisation plans.

And here’s the part too many boards miss: the ransom is only the start of the damage.

• Share price impact: Public disclosures of ransomware routinely knock 3–5% off market cap. One company’s 2023 breach wiped millions in value overnight.
• Investor attraction: If you can’t prove your research data is safe, investors won’t touch you. Due diligence now treats ransomware resilience like another line in your balance sheet.
• Time-to-market delays: Every month of R&D delay costs millions in burn and kills first-mover advantage. In pharma, a six-month delay can add $3–6M to costs.
• Commercialisation risk: Stolen formulas and trial data can create “prior art” that undermines your patents. Translation: your billion-dollar IP is now legally copyable.

Ransomware isn’t just an IT outage — it’s a strategic risk to valuation, market entry, and investor confidence.

49% of Private Equity deals fail because of undisclosed data breaches

Why R&D-intensive companies are vulnerable

Think of your R&D program as a fragile supply chain. Every stage — discovery, trials, data integrity, and commercialisation — depends on governance and control. When ransomware strikes, the weak links show.

Here’s an uncomfortable truth: in R&D intensive businesses, many ransomware vulnerabilities come not from exotic zero-day cyber exploits but from poor data governance, which flows through to your information security posture. Data governance is not a “tech” term — it’s a board-level responsibility. When governance fails, attackers thrive:

• Unclear ownership and access: If no one owns the data, no one protects it. Attackers love overexposed research folders and outdated VPN access.
• Failed backups: Governance blind spots mean backups aren’t tested — so the first time you discover they don’t work is during an attack.
• Misapplied controls: Without proper data classification, security teams guard low-value data while leaving crown jewels exposed.
• Regulatory exposure: Weak governance makes GDPR, HIPAA, or ISO non-compliance almost inevitable — and regulators don’t accept “we were hacked” as an excuse.
• Slow detection: Without adequate security monitoring, attackers can sit inside your network for weeks undetected, rehearsing their attack.

Poor governance contributes to a perfect operating environment for ransomware groups. And in R&D-heavy sectors, that means your valuation is basically gift-wrapped for attackers.

The professionalisation of ransomware in 2025: the 8-step targeting cycle

Forget the old “spray and pray” model where attackers blasted out phishing emails and hoped someone clicked. That was cybercrime’s stone age, and focused on everyone and everything rather than being highly sophisticated, targeted, and selective.

Today’s ransomware gangs are professionals. They behave like organised crime syndicates, following a structured 8-step targeting cycle designed to maximise pressure and payouts:

1. Target Selection – Industries where data equals enterprise value, such as pharma, biotech, semiconductors, medtech, and advanced manufacturing.
2. Initial Surveillance – Public sources, leaked credentials, and open servers help attackers map your weak spots.
3. Final Target Selection – They zoom in on firms with high-value IP, fragile governance, and patchy defences.
4. Pre-attack Surveillance – Once inside, they quietly watch. Mapping networks, spotting backup systems, and studying user behaviours.
5. Planning – With insider-level intel, attackers script their playbook for maximum damage and leverage.
6. Rehearsal – Yes, they practice. In test environments, they run through encryption and data theft to ensure nothing goes wrong on game day.
7. Execution – Systems are locked, IP is exfiltrated, ransom notes drop. Victims are blindsided; attackers are already two steps ahead.
8. Escape & Evasion – Logs are wiped, trails covered, backdoors left behind for future profit.

This is not opportunistic crime conducted by pimply teenagers. It’s deliberate, researched, and ruthlessly commercial — closer to an IPO roadshow than a smash-and-grab.

Case studies: when ransomware hit the labs

Perhaps your one of the many people I talk to at industry events who’s sick of hearing about security. Well, if you need further convincing on the importance of this topic here are 5 real-world examples that show how professionalised ransomware plays out:

Company	Attacker Group	Success Factors	Business Impact	IP/Patent Risk
Company A (India, 2023)	ALPHV / BlackCat	Compromised VPNs & stolen credentials, extensive pre-attack surveillance.	17TB of data stolen, 3–5% share price drop, $50–62M revenue hit, $3M+ recovery costs.	Risk of patent invalidation if leaked as prior art.
Company B (Japan, 2023)	Unnamed (likely RaaS affiliate)	Supply chain intrusion, privileged access exploitation.	Multi-week disruption of R&D and manufacturing, investor concern.	Possible exposure of neuroscience research.
Company C (India, 2020)	Unnamed criminal ransomware group	Phishing & credential theft during COVID-19 trials.	4% share price drop, 2-week trial delays, $150k–$250k added burn per project.	Trial data exposure undermines exclusivity.
Company D (Germany, 2023)	Unnamed RaaS affiliates with APT links	Exploited enterprise / cloud vulnerabilities, targeted R&D repositories.	Attack contained quickly, limiting share price impact.	Potential R&D data exposure, though managed.
Company E (UK, 2024/25)	Qilin	VPN / firewall exploits (CVE-2024-21762), targeted NHS-critical systems.	£32.7M loss (~$41M), weeks of disruption, ransom ~$50M.	Diagnostic IP exposed, R&D collaborations disrupted.

The costs of an IP breach

Conclusion: the strategic picture

The uncomfortable truth: ransomware groups have professionalised faster than most boardrooms have adapted. They’re running playbooks that look like government intelligence operations, and they’re aiming squarely at industries where research is the business to make sure you’re highly incentivised to pay up.

If you’re in an R&D-intensive sector, you’re not just another target — you’re the main course. Weak governance, patchy security, and misplaced confidence in cyber insurance won’t save you.

So, next time someone in the boardroom calls ransomware an “IT problem,” remind them it’s actually a governance problem. Because in 2025, the attackers aren’t amateurs anymore — and if your business wants to survive your response can’t be either.

Further Reading

1. Curwell, P. (2023). The Costs of an IP Breach
2. Curwell, P. (2024). 49% of Private Equity deals fail because of undisclosed data breaches
3. Curwell, P. (2024). Cybercriminals Steal $5 Trillion Every Year from businesses like yours – and how you can stop them! LinkedIn
4. Europol (2024). Internet Organised Crime Threat Assessment IOCTA 2024.pdf
5. Resultant – How Ransomware and Data Governance Are Connected (2024)
6. WJARR – Data Governance and Cybersecurity Resilience (2024)
7. OneTrust – 3 Steps for Mitigating the Impact of Ransomware Attacks Through Data Discovery (2023)
8. Atlan – Data Governance vs. Data Security: Why Both Matter (2023)
9. LinkedIn (Mark Shell) – Data Governance: The Final Frontier for Ransomware Protection (2024)
10. BlueZoo – Safeguarding Sensitive Information Through Governance and Security (2024)
11. Bitsight – Security Ratings and Ransomware Correlation (2023)
12. Varonis – Ransomware Statistics You Need to Know (2025)
13. ACIG Journal – Ransomware: Why It’s Growing and How to Curb It (2024)

DISCLAIMER: All information presented on PaulCurwell.com is intended for general information purposes only. The content of PaulCurwell.com should not be considered legal or any other form of advice or opinion on any specific facts or circumstances. Readers should consult their own advisers experts or lawyers on any specific questions they may have. Any reliance placed upon PaulCurwell.com is strictly at the reader’s own risk. The views expressed by the authors are entirely their own and do not represent the views of, nor are they endorsed by, their respective employers. Refer here for full disclaimer.